#Parkinson #Cognition #Inflammation #IL6 #Entacapone #MoCA
Parkinson’s disease (PD) is a
progressive
neurodegenerative disorder primarily characterized by motor symptoms such as
tremors, rigidity, and bradykinesia. However, in moderate to advanced stages,
non-motor symptoms—particularly cognitive impairments—become increasingly
common, affecting memory, attention, executive function, and information
processing speed. These cognitive issues significantly impact quality of life,
reduce independence, and complicate overall disease management.
Traditional dopaminergic treatments,
particularly the combination of levodopa and carbidopa (LC), help control motor
symptoms in the short term. However, their effectiveness tends to diminish over
time, and their impact on cognition remains limited. Given these therapeutic
limitations, new strategies are being explored to address the non-motor
dimensions of PD.
In this context, the addition of
entacapone—a
catechol-O-methyltransferase (COMT) inhibitor—to the LC combination has
attracted particular interest. This triple combination, known as
levodopa-carbidopa-entacapone (LCE), extends the effect of levodopa by reducing
its peripheral degradation, thereby ensuring better dopamine availability in
the brain. Beyond its motor benefits, this prolonged dopaminergic modulation
may also have positive effects on certain brain functions, especially cognitive
ones.
This study explores
the impact of LCE on
cognitive function and
systemic inflammation, particularly using the MoCA score
and IL-6 levels, in patients with moderate to advanced Parkinson’s disease.
What if we boosted memory too?
Eighty patients with moderate to advanced Parkinson’s disease were enrolled in
the study and randomly assigned to one of two groups:
- Standard
treatment: levodopa + carbidopa (LC)
- Triple
combination: levodopa + carbidopa + entacapone (LCE)
All participants underwent a comprehensive
evaluation at the beginning and end of the study, including motor tests,
cognitive assessments (notably the MoCA score), emotional assessments (anxiety,
depression), and biological analyses (pro-inflammatory cytokine levels).
The results show a
significant cognitive
improvement in the LCE group, with an average increase of
1.5 points in the
MoCA score (p < 0.001). No significant change was observed in the LC group.
On the biological level, patients treated with LCE also showed a
marked
reduction in serum interleukin-6 (IL-6) levels, a pro-inflammatory cytokine
involved in neurodegeneration (p = 0.002).
A negative correlation was observed
between the drop in IL-6 levels and the improvement in cognitive performance,
suggesting a potential link between peripheral inflammation and brain function
in Parkinson’s patients.
No significant differences between the two
groups were found in terms of motor symptoms, anxiety, or depression. These
findings suggest that adding entacapone may specifically target cognitive and
inflammatory components of the disease, without affecting other clinical
dimensions in the short term.
Read next: IL6 receptor inhibitors: exploring the therapeutic potential of several diseases using Mendelian randomisation of drug targets
LCE: An unexpected cognitive boost?
Parkinson’s disease is a progressive neurological condition often associated
with tremors and motor impairments. In more advanced stages, cognitive
disorders become common and severely affect patients' independence and quality
of life. A major challenge lies in the lack of effective treatments to slow
down or reverse this cognitive decline. While dopaminergic therapies such as
levodopa-carbidopa (LC) relieve motor symptoms, their effect on cognition
remains limited.
This study explores whether the combination of
levodopa-carbidopa-entacapone can improve cognitive function in patients with
Parkinson’s disease. It also examines its biological impact, focusing on IL-6
levels—a pro-inflammatory cytokine potentially linked to cognitive decline.
These findings support the hypothesis of an
indirect therapeutic effect of LCE on cognition, potentially mediated by an
anti-inflammatory action. They suggest a connection between improved cognitive
function and reduced systemic inflammation, notably through IL-6 modulation.
However, several limitations remain, and further clinical trials are needed to
confirm these initial observations and better define responder profiles.
This study lays the groundwork for a new
strategy:
targeting inflammation to protect cognitive function.
What if, in
Parkinson’s disease, preserving the mind also meant acting on the immune
system?
Read next: The impact of loneliness on Parkinson’s Disease
